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Traumaticinjurytothespinalcordresultsinmultipleanatomical,physiological,andfunctionaldeﬁcitsasaresultoflocalneuronal
and glial cell death as well as loss of descending and ascending axons traversing the injury site. The many diﬀerent mechanisms
thought to contribute to protracted secondary cell death and dysfunction after spinal cord injury (SCI) are potential therapeutic
targets. Agents that bind and activate the transcription factor peroxisome proliferator-activated receptor-γ (PPAR-γ) show great
promiseforminimizingorpreventingthesedeleteriouscascadesinothermodelsofCNSdisorders.Thisreviewwillsummarizethe
major secondary injury cascades occurring after SCI and discuss data from experimental CNS injury and disease models showing
the exciting potential for PPARγ therapies after SCI.
Copyright © 2008 Dana M. McTigue. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. WHAT IS PPARγ?
“PPAR” is an acronym for peroxisome proliferator-activated
receptor, which refers to a family of nuclear hormone recep-
tors that function as ligand-activated transcription factors.
Three PPAR isoforms have been identiﬁed to date, including
PPARα,P P A R β/δ,a n dP P A R γ (for review, see [1–3]). Upon
activation, PPAR molecules heterodimerize with retinoid X
receptors (RXRs), which are the nuclear receptors for 9-cis
retinoic acid. After dimerization, the PPAR/RXR complex
binds tospeciﬁc promoter sequenceson target genes whereit
can promote or repress gene activation. Most initial research
on these molecules focused on their role in lipid metabolism
andhomeostasis[1,4].However,itisnowknownthatPPARs
function in a much broader array of physiological functions,
both under normal conditions and following injury or dis-
ease. In particular, upregulation of PPARγ mRNA has been
detected in inﬂammatory cells and in experimental models
of CNS injury such as ischemic stroke [5, 6]. PPARγ ago-
nists appear to have potent anti-inﬂammatory and neuro-
protective actions [7–9]; thus, this transcription factor may
be involved in coordinating cellular responses to CNS injury.
This also presents the opportunity to enhance neuroprotec-
tionbyleveragingPPARγ expressionthroughadministration
of speciﬁc agonists following CNS damage. Indeed, over the
pastdecade,severalstudieshaverevealedbeneﬁcialactionsof
promotingPPARγ activationinexperimentalmodelsofCNS
injury, ischemia, and disease. Less work has examined the
potential of promoting PPARγ activation following injury to
the spinal cord, for which current clinical therapies are lim-
ited. This review will summarize the documented beneﬁcial
actions of PPARγ following CNS injury and illustrate how
they may also promote anatomical and behavioral recovery
after spinal cord injury (SCI).
2. SPINAL CORD INJURY: THE FACTS
In the United States, a new SCI is sustained on average ev-
ery 41 minutes, which results in ∼1100 new cases each year.
Themajorityoftheseinjuriesarecausedbymotorvehicleac-
cidents, followed by accidents such as falling from ladders or
diving into shallow water[10]. Most SCI’s occur in young in-
dividuals, particularly males—in their late teens or twenties.
Because medical care has improved dramatically during the
previous century, most individuals can expect to live many
years following an SCI. Their lives, however, are not easy and
they have many issues with which to deal on a daily basis. In
theeyesofmostuninjuredpeople,themostobviousproblem
aﬀecting SCI individuals is their inability to walk. While this
is clearly a signiﬁcant obstacle to overcome, a recent survey2 PPAR Research
of paraplegics and quadriplegics revealed that regaining lo-
comotor function is actually of lesser importance to them
compared to the many other issues they face [11]. For in-
stance, quadriplegics would prefer restoration of hand and
arm function over walking. Paraplegics’ top choice would
be regaining normal sexual function, an important issue in
terms of relationships with signiﬁcant others, and the ability
to have a family. Also high on the list for all spinal-injured
people was return of bowel and bladder function. Other seri-
ous issues many face include potentially fatal autonomic dys-
reﬂexia, pressure sores that can take several months to heal,
and untreatable intractable pain [10].
Since it is impossible to prevent the occurrence of most
SCIs,ourbesthopeistoimprovethelevelofrecoveryachiev-
able after an SCI occurs. Most SCIs result from a contusion-
type injury in which the vertebral bodies and/or interverte-
bral discs are rapidly displaced into the spinal canal causing
crushing and bruising of the delicate spinal tissue [12, 13].
The initial impact leads to immediate hemorrhage and rapid
cell death at the impact site. This is followed by multiple sec-
ondary injury cascades that cause further tissue loss and dys-
function [10, 14]. If these secondary injury processes were
minimized or eliminated, the outcome for patients would be
greatly improved. Many of these cascades are potential tar-
gets for intervention by activation of the transcription factor
PPARγ. Indeed, two recent studies demonstrated that treat-
ment of SCI rodents with a PPARγ agonist results in signiﬁ-
cantly improved anatomical sparing and locomotor abilities
[15,16].Therestofthisreviewwilldiscussspeciﬁcsecondary
injury processes that occur after SCI and how PPARγ activa-
tion may be used to lessen their impact.
3. GLUTAMATE EXCITOTOXICITY:
A GOOD TRANSMITTER GONE BAD
Within minutes of SCI, extracellular glutamate levels rise
within and around the injury site [17]. This potent neuro-
transmitter can then diﬀuse to surviving cells, bind to sur-
face receptors, and lead to what is known as excitotoxic cell
death [18]. Especially vulnerable to excitotoxicity are neu-
rons and oligodendrocytes, which express a full complement
of glutamate receptors. Loss of neurons at the injury site will
lead to direct denervation and paralysis of muscle ﬁbers in-
nervated by those neurons, thereby contributing to motor
deﬁcits. Because a signiﬁcant amount of sensory processing
occurs within the spinal cord, especially that involved in pain
and temperature sensation, loss of neurons can also lead to
hypersensitivity, paresthesia, enhanced and prolonged pain,
and/or total loss of pain and temperature sensation. Excito-
toxic injury to oligodendrocytes can result in demyelination
of axons around the injury site. This, in turn, will lead to
a drastic reduction or complete halt of axonal transmission,
thereby enhancing the disconnection between the brain and
spinal segments below the level of injury. Thus, excitotoxi-
city has the potential to markedly exacerbate the functional
problems encountered after SCI. Indeed, the involvement of
excess glutamate in cell death after SCI was demonstrated by
studies in which early treatment with glutamate antagonists
signiﬁcantly enhanced tissue preservation and functional re-
covery following SCI in rats [19, 20].
A major mechanism responsible for maintaining low ex-
tracellular glutamate levels is astrocytic uptake via glutamate
transporters, including GLT1/EAAT2 which is responsible
for removal of up to 90% of extracellular glutamate. While
glutamate transporters are eﬀective under basal conditions,
they become saturated when glutamate levels rise substan-
tially above normal. Thus, a mechanism for increasing ex-
pression of GLT1/EAAT2 and other glutamate transporters
could be highly beneﬁcial after SCI. Recent work reveals that
PPARγ activationmaydojustthat.Usingacellculturemodel
of ischemic preconditioning, Romera et al. [21] showed that
preconditioning upregulates PPARγ expression in neurons
and astrocytes, and that treatment of the cultures with a
PPARγ agonist signiﬁcantly increased astrocytic expression
of GLT1/EAAT2 mRNA and protein. They also showed that
this increased expression translated into enhanced glutamate
uptakeandreducedcelldeath.Theproposedmechanismwas
a direct increase in EAAT2 promoter activity induced by ac-
tivatedPPARγ.Adirectneuroprotective actionbyPPARγ ac-
tivation under excitotoxic conditions has also been demon-
strated using cultures of pure cortical neurons [22]. In vivo
evidence supports the notion that PPARγ activation is pro-
tective against glutamate excitotoxicity. For instance, treat-
ment with a PPARγ agonist decreased neuron loss caused by
intracortical injection of a glutamate receptor agonist [22].
While changes in glutamate levels in SCI models treated
with PPARγ agonists have not yet been measured, protection
against glutamate excitotoxicity is a plausible mechanism by
which PPARγ could improve outcome after SCI.
4. LIPID PEROXIDATION
A well-documented pathological process occurring early af-
ter SCI is the formation of reactive oxygen and nitrogen
species (ROS and RNS, resp.); this results from increased in-
tracellularcalciumlevels,mitochondrialdysfunction,arachi-
donic acid breakdown, and activation of inducible nitric ox-
ide synthase (iNOS) [23–25]. Initially thought to be a prob-
lem only in acute SCI tissue, newer studies have revealed
that indices of free radical damage are present throughout
the ﬁrst week after injury [26, 27]. ROS and RNS cause
lipid peroxidation as well as oxidative and nitrative dam-
age to proteins and nucleic acids [27, 28]. In addition, ox-
idative damage exacerbates mitochondrial dysfunction [29]
and contributes to intracellular calcium overload which ac-
tivates proteases resulting in breakdown of cytoskeletal pro-
teins [27, 30]. Thus, the collective damage induced by ROS
and RNS is far-reaching and likely contributes to cellular
death and functional loss after SCI.
PPARγ activationafterSCIcoulddampenthedamagein-
duced by ROS and RNS in multiple ways. First, PPARγ acti-
vation may reduce the overall level of free radicals present
in the injured tissue since PPARγ activation leads to de-
creased nitric oxide, cyclooxygenase-2 (COX-2), iNOS, and
nitrotyrosine levels in animal models of amyotrophic lateral
sclerosis (ALS), multiple sclerosis (MS), ischemia, and neu-
roinﬂammation [31–37]. In addition, PPARγ agonists mayDana M. McTigue 3
increase the levels of antioxidants in or around the injured
tissue. For instance, catalase levels were elevated by PPARγ
agonist treatment following intracerebral hemorrhage [38];
with increased antioxidant levels, the surviving tissue will be
betterequippedtofendoﬀassaultbyfreeradicals.Thus,ago-
nists that stimulate PPARγ may reduce the levels of free radi-
cals and at the same time, elevate enzymes essential for com-
bating free radicals that remain. This in turn would reduce
the number of neurons and glial cells that die in the subacute
phase of SCI. Studies by our group and others have shown
that treatment with the PPARγ agonist pioglitazone resulted
in an increase in the number of motor neurons spared after
SCI, which might have been due, at least in part, to a reduc-
tion in post-SCI oxidative damage [15, 16]. By promoting
motor neuron survival in human SCI, signiﬁcant preserva-
tion of segmental function may be possible. Although com-
pleterecoveryof“normal”functionmaynotbefeasible,even
partial recovery of hand function, for instance, could drasti-
cally improve the quality of life for an individual with SCI.
5. INFLAMMATORY-MEDIATED CELL DEATH
A well-characterized event after spinal trauma is local mi-
croglial activation, inﬂammatory cell inﬁltration, and up-
regulation of proinﬂammatory mediators. Indeed, several
studies have shown the rapid rise in proinﬂammatory cy-
tokines and chemokines which stimulate inﬂammatory cell
inﬁltration into the injured spinal cord [14]. Once present
within the damaged and surrounding parenchyma, in-
ﬂammatory cells such as neutrophils, macrophages, and
lymphocytes can exacerbate tissue damage. For instance,
activated macrophages and microglia produce cytotoxic
molecules such as iNOS, TNFα,I L - 1 β, and IL-6. Interest-
ingly, PPARγ levels are upregulated in activated microglia
and macrophages [35, 39, 40] and activation of PPARγ in
these cells can decrease production of proinﬂammatory me-
diators [40–42]. The mechanisms contributing to these ef-
fects include antagonism of AP-1, STAT, and NFκBl e v -
els as well as concomitant increases in IκBα levels. Collec-
tively, these actions will reduce the inﬂammatory poten-
tial of the treated cells [37, 38, 40, 43]. Accordingly, PPAR-
induced inhibition of microglia/macrophage accumulation
and release of proinﬂammatory cytokines has been detected
in animal models of Alzheimer’s disease, Parkinson’s dis-
ease, and MS [33, 34, 44–46]. PPARγ activation can also
reduce the diﬀerentiation of monocytes into macrophages
[45], promote macrophage apoptosis [47], and decrease T-
cell proliferation, which collectively would result in reduced
numbers of inﬁltrating inﬂammatory cells into the injured
spinal cord [48]. Indeed, PPARγ-induced reductions in neu-
trophil, T-cell, and macrophage inﬁltration have been shown
in animal studies of experimental allergic encephalomyeli-
tis (EAE, an animal model of MS) and intracerebral hem-
orrhage [33, 38, 48] .T h i sm a yb ed u e ,i np a r tt o ,aP P A R γ-
mediated reduction in chemokines, which elicit inﬂamma-
torycellrecruitmenttotheCNS.Forinstance,micewithEAE
given oral PPARγ agonists expressed lower levels of MIP1α
and RANTES within the brain compared to control mice
[33].
Collectively, these data suggest that PPARγ activation
provides a potent means for reducing proinﬂammatory me-
diators afterCNS injury,including traumatothespinal cord.
ThisisfurthersuggestedbyrecentSCIstudieswhichrevealed
a reduction in gliosis, cytokines, and adhesion molecules
[16]. Many SCI studies have demonstrated that postinjury
treatment with anti-inﬂammatory agents results in signif-
icantly improved anatomical and functional recovery [49–
54]. Thus, the anti-inﬂammatory actions of activating the
PPARγ pathway could provide another mechanism for re-
ducing the deleterious proinﬂammatory cascades initiated
after SCI.
6. DEMYELINATION OF SURVIVING AXONS AFTER SCI
Another pathological feature of acute and chronic SCI tissue
is demyelination of axons that survive the initial traumatic
event [55–57]. Loss of myelin will lead to conduction de-
lays and/or frank conduction block. Because axons travers-
ing the injury site are the sole remaining connection be-
tween the brain and caudal spinal neurons, ineﬃcient com-
munication through these axons is a signiﬁcant clinical is-
sue. Demyelination is due to loss of oligodendrocytes, which
are killed at the injury epicenter within hours of the injury
and continue to undergo apoptosis in rostral and caudal
whitematterformanyweeksafterSCI[58–60].Thepotential
mechanisms responsible for acute and delayed oligodendro-
cyte death are numerous. For instance, oligodendrocytes are
known to be susceptible to glutamate excitotoxicity, which
could contribute to the early loss of these cells. Oligodendro-
cytesandtheirmyelinmembranesarealsovulnerabletolipid
peroxidation, which,asstated above,is prevalentthroughout
theﬁrstweekafterinjury.Lastly,proinﬂammatorymediators
such as TNFα and IL-1β can lead to oligodendrocyte death.
Since PPARγ activation can counteract many of these
deleterious processes, this pathway may thereby promote
oligodendrocyte survival and myelin preservation follow-
ing CNS damage. Indeed, treatment with a PPARγ agonist
markedly improved myelination and decreased lesion area in
the CNS of animals with EAE [33, 44, 48, 61]. In addition,
aP P A R γ agonist was able to reduce myelin damage in an in
vitro model of inﬂammatory demyelination [62]. Therefore,
treatment with PPARγ agonists after SCI could potentially
lead to improved oligodendrocyte survival and better myelin
preservation. Indeed, we have noted that when the PPARγ
agonist pioglitazone was given to rats after SCI, a signiﬁcant
increase in sparing of white matter distal to the lesions was
detected [15]. This likely contributed to the improved loco-
motor function detected in our study and others [15, 16].
Thus, acute treatment of SCI patients with a PPARγ agonist
could potentially improve tissue sparing and thereby allow
for a greater level of locomotor abilities as well as other im-
portant functional outcomes. For example, neurons control-
ling bowel and bladder function are located within the lower
spinal cord, including the lumbar and sacral segments. Be-
cause most SCI’s occur in more rostral segments, neuronal
circuits that directly control bowel and bladder are often in-
tact after SCI. However, signiﬁcant and permanent bowel
and bladder dysfunction occurs due to loss of descending4 PPAR Research
Table 1: Summary of eﬀects mediated by PPARγ activation in CNS injury or disease models.
Disease/injury model Known PPARγ eﬀects References
Spinal cord injury
  ⏐locomotor recovery
[15, 16]
  ⏐myelin sparing
  ⏐motor neuron sparing
⏐  glial activation
⏐  proinﬂammatory cytokines
Experimental allergic
encephalomyelitis
(model of multiple
sclerosis)
  ⏐myelin sparing
[33, 44, 48, 61]
⏐  lesion size
⏐  inﬂammatory cell inﬁltrate
⏐  proinﬂammatory cytokines & chemokines
⏐  clinical score (better recovery; lower no. of relapses)
Amyotrophic lateral
sclerosis
  ⏐motor neuron survival
[32]
⏐  glial activation
⏐   COX-2
⏐   iNOS
  ⏐longevity, delayed disease onset
Parkinson’s disease
  ⏐dopaminergic neuron survival
[43, 46]
⏐  gliosis
⏐   iNOS
⏐   NFκB translocation to the nucleus
  ⏐ IκBα
Cerebral ischemia
  ⏐neuron survival in penumbra
[6, 31, 35, 37, 64]
⏐   lesion size
⏐  COX-2
⏐   proinﬂammatory cytokines
  ⏐ antioxidants
Cerebral hemorrhage
  ⏐ catalase
[38]
⏐  NFκB
⏐   neutrophil inﬁltration
⏐   apoptosis
⏐   behavioral dysfunction
Alzheimer’s disease
⏐  gliosis
[7, 45, 65, 66]
⏐  COX-2 & iNOS
⏐  proinﬂammatory cytokines
⏐  Aβ1-42+ amyloid plaques
⏐  β-secretase mRNA
⏐  monocyte diﬀerentiation into macrophages
signals carried by axons that are lost or demyelinated at the
impact site. Therefore, enhanced preservation of myelin or
promotion of remyelination at the injury site could lead to
functionally signiﬁcant improvements in the quality of life
for SCI patients.
7. NEURON LOSS AFTER SCI
Contusion-type injuries are the most commonly sustained
trauma to the spinal cord. Because of the high degree of
vascularization and the dynamic forces encountered within
the gray matter during contusive injuries [63], the lesions
evolve as centralized ﬂuid-ﬁlled cavities originating within
gray matter regions at the lesion site that extend into ros-
tral and caudal segments. Thus, even mild contusions can
result in signiﬁcant neuron loss over multiple segments of
spinal cord. As stated above, neurons not killed by the initial
impact can fall victim to secondary cascades, including is-
chemia, excitotoxicity, lipid peroxidation, and proinﬂamma-
tory mediators. This neuron death will lead directly to loss of
function in the muscles innervated by motor neurons at the
segment of injury. Since the majority of injuries occur in the
cervical spinal cord, SCI often means loss of function in the
arms and hands. In addition, motor neurons driving respira-
tionarefoundwithinC3–C5,soinjuriesthatdirectlydamage
these segments frequently result in respirator dependence.Dana M. McTigue 5
Clearly, therapies that protect neurons from secondary
injury cascades after SCI are of great importance. Given the
potential beneﬁcial actions of PPARγ activation discussed
above, neuroprotection after SCI is an important poten-
tial therapeutic target for PPARγ agonists. Indeed, improved
neuronal survival following PPARγ agonist treatment has al-
ready been noted in several models of CNS disorders. For in-
stance, treatment with the PPARγ agonist pioglitazone pro-
moted motor neuron survival and increased muscle ﬁber di-
ameter in a transgenic model of ALS [32]. PPARγ agonists
also increased neuron survival and decreased lesion sizes in
models of Parkinson’s disease [43, 46], central inﬂammation
[34], intracerebral hemorrhage [38], and cerebral ischemia
[5, 6, 31, 35]. These beneﬁcial eﬀects were likely mediated
through a reduction in the indirect actions noted above, in-
cluding lipid peroxidation, proinﬂammatory signals, and ex-
tracellular glutamate levels. However, PPARγ activation may
also have a direct eﬀect on neurons. Neuronal expression of
PPARγ has been detected in the intact CNS and an upreg-
ulation of PPARγ was observed in neurons in the ischemic
penumbra following focal cerebral ischemia [5, 6, 31, 35].
Furthermore, cultured neurons treated with PPARγ agonists
were protected from glutamate-induced death demonstrat-
ing a direct action of PPARγ activation in neurons [22].
Thus, if a PPARγ agonist was delivered soon after SCI, signif-
icant neuronal sparing may be achieved which would likely
translate into better functional preservation and improved
quality of life for SCI patients.
8. SUMMARY
The PPAR pathway appears to play an important role in re-
covery from CNS disorders (Table 1). Indeed, several studies
suggestthatendogenousligandspresentinthedamagedCNS
can activate the PPARγ pathway and contribute to anatom-
ical preservation. This is illustrated by studies demonstrat-
ing that PPARγ antagonists potentiate tissue pathology af-
ter cerebral ischemia [5, 6]. Exacerbation of neuropathology
also occurs when EAE is induced in the presence of a PPARγ
antagonist or when disease is induced in PPARγ knockout
mice [61, 67]. Thus, endogenous PPARγ activation may be
an essential component of promoting spontaneous repara-
tive mechanisms that are initiated in the injured brain and
spinal cord. This endogenous response appears submaximal,
however, as the numerous studies discussed above suggest
that pharmacological activation of the PPARγ pathway sub-
sequenttodamagemaysigniﬁcantlyimproverecovery.Inthe
realmofSCIresearch,treatmentsareseverelylacking.There-
fore, manipulating the PPARγ pathway appears to hold great
potential as a therapy for treating human SCI.
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